Date Time Place Information

See older events

Date Time Place Information
July 6, 2020
New paper in Nature Medicine by David Tamborero
Today, the paper by Tamborero, Dienstmann et al. "Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal" is published in Nature Medicine. This work describes the use of a new precision cancer medicine technology to inform the use of individualised treatments in clinical trials guided by the genomics profile of the tumours. The portal has been developed at Karolinska Institutet and SciLifeLab together with clinical researchers from seven European comprehensive cancer centre enters and has currently analysed more than 500 patients' samples. Our current ability to profile the molecular characteristics of tumours has opened the door to more effective therapies tailored to each patient's disease. However, this has also brought new challenges to the medical teams, which must interpret the gene alterations detected in the patient's tumour and select the most appropriate treatment according to the latest scientific evidence. This process is complicated and time-consuming, and often requires the use of databases and computational tools that are not readily accessible at the clinical setting. As the number of molecular biomarkers continues to grow, the use of new technologies to facilitate genomics data interpretation and knowledge exchange are needed for treatment planning. In response, the Lehtiö lab has developed the Molecular Tumor Board Portal. This clinical decision support system combines a variety of state-of-the-art methods to classify the actionability of genomic tumour alterations and inform clinical interventions. This portal is currently used by a collaborative network of seven European comprehensive cancer centres, which includes the Karolinska University Hospital, under the umbrella of the Cancer Core Europe. The portal has analysed more than five hundred patients in the context of the Basket of Baskets trial (NCT03767075), a multi-arm study for genomically-defined tumours that do not respond to standard-of-care therapies. This experience is published today in Nature Medicine. "The portal automates the data interpretation, which eliminates potential errors due to manual processes and provides a systematic analysis based on expert consensus criteria", says David Tamborero, senior researcher at Karolinska Institutet SciLifeLab, and leading scientist of the project; "The use of this platform also avoids delays in the delivery of the results, which is critical for patients whose condition may rapidly deteriorate". The portal provides the framework to share the results via patient-centric reports accessible in a secure, web-based application. These reports are data-rich interactive documents discussed during weekly virtual meetings, in which multidisciplinary representatives from each Cancer Core Europe centre agree on clinical actions. "From an oncologist view, the system has changed how we work. By using the portal in molecular tumor boards we have easy access to the latest knowledge on cancer mutations and can discuss the cases with colleagues from all the seven centres in a truly collaborative manner", says Rodrigo Dienstmann, Principal Investigator of the Oncology Data Science Group of the Vall d'Hebron Institute of Oncology. The authors describe a learning curve to use the technology lasting for approximate twenty-five reviewed patients. After that, the amount of time devoted to discussing each case rarely exceeds a few minutes, which is critical to scale the data-driven decision process to a large number of patients. As a resource to investigators outside of the Cancer Core Europe network, an open access version of the Molecular Tumor Board Portal genomics interpretation pipeline has been made available at "We believe that the use of the portal in the clinical setting is key to accelerate the translation of new research discoveries to the patients' benefit", says Janne Lehtiö, professor at Karolinska Institutet and scientific director of SciLifeLab. "We are currently working to incorporate data from emerging biomarkers such as proteomics and digital pathology in the portal "further to improve the selection of the treatment for each patient.
March 25, 2019
VHIO Barcelona
4th Annual meeting of Cancer Core Europe
The 4th Annual meeting of Cancer Core Europe takes place in Barcelona, beteen March 25-26. The 2019's agenda will focus on the Cancer Core Europe work and projects, and include task force presentations with discussions where everyone can contribute, as well as cross task force discussions and project specific gatherings.
October 1, 2019
Campus Solna Biomedicum D1012, 10th floor, Solnavägen 9, Campus Solna
Cell and Tumour Biology Seminar: From conventional Cancer treatment to Precision Cancer Medicine (PCM) and beyond